| Literature DB >> 33841543 |
Roya Pournejati1,2, Ronald Gust2, Brigitte Kircher3,4, Hamid Reza Karbalaei-Heidari1.
Abstract
Screening of bioactive compounds with potential binding affinity to DNA as one of the target molecules in fighting against cancer cells has gained the attention of many scientists. Finding such compounds in the cellular content of microorganisms, especially marine bacteria as valuable and rich natural resources, is of great importance. Microbacterium sp. RP581, as a member of Actinobacteria phylum, was isolated from the Persian Gulf coastal area and the production of the target compound was optimized using statistical methods in cheap culture ingredients. The purification of the target compound was performed by flash chromatography and preparative HPLC. Both molecular and structural analyses indicated that the compound was an indole derivate which was tentatively named as Microindoline 581. Interaction of Microindoline 581 with genomic and circular DNA revealed that this compound can cause double- strand breaks through binding to the DNA. The analysis of cellular growth and proliferation of various cancer cell lines suggested proper and specific effect of the Microindoline 581 towards HepG2 cells with an IC50 of 172.2 ± 1.7 µM. Additional studies on cell migration inhibition and cell-death induction indicated a concentration-dependent inhibitory effect on proliferation and induction of death of HepG2 cells. The selective action of Microindoline 581 which was isolated from the Microbacterium sp. RP581 in killing HepG2 cells might be due to its specific metabolism in those cells as a precursor.Entities:
Keywords: DNA damage; Hepatocellular carcinoma; Microbacterium sp.; Microindoline; Natural products
Year: 2020 PMID: 33841543 PMCID: PMC8019894 DOI: 10.22037/ijpr.2020.111982.13469
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Experimental results for 2 level fractional factorial design
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 0.65 | 0.89 ± 1.47 | +1 | -1 | -1 | -1 | -1 | 1 |
| 5.17 | 4.99 ± 2.12 | -1 | -1 | -1 | -1 | +1 | 2 |
| 24.74 | 38.3 ± 16.9 | -1 | -1 | -1 | +1 | -1 | 3 |
| 82.02 | 91.07 ± 0.68 | +1 | -1 | -1 | +1 | +1 | 4 |
| 23.2 | 48.51 ± 10.35 | -1 | -1 | +1 | -1 | -1 | 5 |
| 71.49 | 81.62 ± 15.34 | +1 | -1 | +1 | -1 | +1 | 6 |
| 31.29 | 95.04 ± 0.43 | +1 | -1 | +1 | +1 | -1 | 7 |
| 50.06 | 61.06 ± 15.66 | -1 | -1 | +1 | +1 | +1 | 8 |
| 21.75 | 28.48 ± 5.42 | -1 | +1 | -1 | -1 | -1 | 9 |
| 1.2 | 2.13 ± 1.4 | +1 | +1 | -1 | -1 | +1 | 10 |
| 8.53 | 13.33 ± 3.33 | +1 | +1 | -1 | +1 | -1 | 11 |
| 53.45 | 87.81 ± 5.86 | -1 | +1 | -1 | +1 | +1 | 12 |
| 42.46 | 91.16 ± 3.66 | +1 | +1 | +1 | -1 | -1 | 13 |
| 69.91 | 91.51 ± 5.07 | -1 | +1 | +1 | -1 | +1 | 14 |
| 8.45 | 11.94 ± 2.17 | -1 | +1 | +1 | +1 | -1 | 15 |
| 88.89 | 88.9 ± 6.012 | +1 | +1 | +1 | +1 | +1 | 16 |
The spherical central composite design (CCD) including percentages of “Cell death”, “Response” and “Predicted response”.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 7.72 | 9.22 | 15.64 ± 3.55 | -1 | -1 | -1 | 1 |
| 48.84 | 52.96 | 98.53 ± 1.73 | -1 | -1 | +1 | 2 |
| 55.54 | 62.45 | 97.34 ± 2.51 | -1 | +1 | -1 | 3 |
| 78.16 | 83.08 | 98.45 ± 1.63 | -1 | +1 | +1 | 4 |
| 18.88 | 18.64 | 40.32 ± 4.56 | +1 | -1 | -1 | 5 |
| 21.04 | 20.24 | 23.51 ± 4.85 | +1 | -1 | +1 | 6 |
| 25.08 | 25.63 | 50.98 ± 3.54 | +1 | +1 | -1 | 7 |
| 11.24 | 14.4 | 32.8 ± 1.95 | +1 | +1 | +1 | 8 |
| 22.62 | 19.38 | 27.05 ± 2.01 | 0 | 0 | -1.73 | 9 |
| 46.22 | 44.89 | 64.52 ± 1.1 | 0 | 0 | +1.73 | 10 |
| 21.83 | 17.65 | 37.24 ± 4.87 | 0 | -1.73 | 0 | 11 |
| 43.05 | 40.64 | 70.32 ± 0.2 | 0 | +1.73 | 0 | 12 |
| 58.18 | 49.93 | 49.93 ± 14.24 | -1.73 | 0 | 0 | 13 |
| 9.94 | 11.61 | 16.21 ± 7.32 | +1.73 | 0 | 0 | 14 |
| 78.37 | 73.42 | 99.24 ± 0.1 | 0 | 0 | 0 | 15 |
| 78.37 | 75 | 95.41 ± 4.27 | 0 | 0 | 0 | 16 |
| 78.37 | 80.43 | 97.31 ± 2.67 | 0 | 0 | 0 | 17 |
| 78.37 | 83.36 | 97.45 ± 3.39 | 0 | 0 | 0 | 18 |
| 78.37 | 75.74 | 97.07 ± 2.03 | 0 | 0 | 0 | 19 |
| 78.37 | 82.24 | 97.45 ± 3.02 | 0 | 0 | 0 | 20 |
Figure 1Carbon and nitrogen source selection experiment. Microbacterium sp. RP 581 biomass and the organic extract production with respect to media number
Figure 23D graph of three independent variables and their interaction in RSM experiments
Figure 31H NMR spectra and proposed structure of Microindoline 581
Figure 4Fluorescence spectra of Microindoline 581 and F-DNA interaction. The Microindoline 581 (90 µM) was incubated with a range of F-DNA concentration (0-172 µM). The Stern –Volmer plot of binding was drawn
Figure 5Gel electrophoresis (1% agarose) of plasmid DNA treated with Microindoline 581; a) lane 1, DNA + H2O2 (50 µM) (negative control), lanes 3-7, DNA + H2O2 (50 µM) treated with 1.5 mM, 2 mM, 2.5 mM, 3 mM and 6 mM of Microindoline 581, respectively, at 37 °C for 1 h; b) lane 2, DNA + H2O2 (50 µM) (negative control), lanes 3-9, DNA + H2O2 (50 µM) treated with 300 µM of Microindoline 581, 1 h, 3 h, 6 h, 9 h, 16 h, 20 h and 24 h, 37 °C respectively; c) lane 1, DNA + H2O2 (50 µM) + 1.5 mM of Microindoline 581, lane 2, DNA + H2O2 (50 µM) + 1.5 mM of Microindoline 581 + 100 µM of DMSO, lane 3, DNA + H2O2 (50 µM) + 1.5 mM of Microindoline 581+ 100 µM of KI, lane 4, DNA + H2O2 (50 µM) + 1.5 mM of Microindoline 581 + 100 µM of EDTA, lane 5, DNA + H2O2 (50 µM) + 1.5 mM of Microindoline 581 + 100 µM of NaN3, lane 6 DNA + 1.5 mM of Microindoline 581 and lane 7, DNA + H2O2 (50 µM) (negative control)
Figure 6. )a) Cell viability determined by MTT assay. Various cancer cell lines were treated with Microindoline 581 (600 µM) for 48 h. The mean viability ± STD of three experiments is shown. Cellular viability in the absence of the compound was set at 100% and) b) Cellular viability of HepG2 cells. Cell viability percentage was determined by MTT and crystal violet assay after treatment with various concentrations of Microindoline 581 for 48 h
Figure 7HepG2 cells migration analysis using scratch assay )a) Control group, )b) HepG2 cells treated with 90 µM of Microindoline 581
Cell death induction in HepG2 cells treated with Microindoline 581 for 24 h
|
|
|
|
|
|
|---|---|---|---|---|
| 0 | 2.95 ± 1.05 | 10.05 ± 0.05 | 2.55 ± 0.25 | 84.35 ± 1.15 |
| 90 | 7.95*** ± 1.05 | 10.80 ± 1.70 | 2.20 ± 0.30 | 79.05* ± 0.35 |
| 147 | 4.9** ± 1.7 | 15.6** ± 0.80 | 13.15** ± 4.25 | 66.35** ± 1.75 |
| 172 | 22.55*** ± 4.65 | 8.45 ± 1.55 | 1.75 ± 0.05 | 67.25** ± 3.05 |
*p-value < 0.05, ** p-value < 0.005, *** p-value < 0.0005.